Healthcare Industry News: King Pharmaceuticals
News Release - June 1, 2009
King Pharmaceuticals Appoints John J. Howarth Vice President Investor RelationsBRISTOL, Tenn.--(HSMN NewsFeed)--King Pharmaceuticals, Inc. (NYSE:KG ) today announced the appointment of John J. Howarth to Vice President, Investor Relations. Mr. Howarth joins King with over 25 years of experience in the healthcare industry, including executive positions at specialty pharmaceutical companies, as well as large global pharmaceutical companies.
“We are extremely pleased to add Jack to our team,” stated Joseph Squicciarino, King’s Chief Financial Officer. “We are confident that Jack’s expertise in investor relations and extensive knowledge of the specialty pharmaceutical industry will complement our senior management team as we focus on executing our long-term growth strategy.”
Most recently, Mr. Howarth was Vice President, Investor Relations at Alpharma Inc., which King acquired in December 2008. Previously, he served in similar roles at MedPointe Pharmaceuticals and Kos Pharmaceuticals. Mr. Howarth received his BS degree in accounting from Boston College and an MBA in finance from Seton Hall University.
About King Pharmaceuticals, Inc.
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company’s focus in specialty-driven markets, particularly neuroscience and hospital. King is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals.
Source: King Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.